Literature DB >> 1314815

Mutational analysis of CD45. A leukocyte-specific protein tyrosine phosphatase.

P Johnson1, H L Ostergaard, C Wasden, I S Trowbridge.   

Abstract

The cytoplasmic domain of murine CD45 has been expressed using an in vitro transcription/translation system. The recombinant protein was isolated by immunoprecipitation with a specific rabbit antiserum and was shown to have protein tyrosine phosphatase (PTPase) activity. Oligonucleotide-directed mutagenesis was then used to investigate the structural requirements for PTPase activity. Although the cysteine crucial for PTPase activity resides in domain I, this domain was not active alone. Both PTPase domains of CD45 and the membrane proximal region of 77 amino acids were required for enzymatic activity. Deletion of 78 residues at the carboxyl terminus of the cytoplasmic region did not influence activity, but an additional deletion of 13 amino acids from PTPase domain II totally abolished activity. Excision of the 21-residue acidic insert in the second PTPase domain resulted in a decrease of activity of approximately 4-fold. Nine conserved residues around the critical cysteine in the first domain were found to be important for activity. Of the 3 conserved tyrosine residues in domain I, only Tyr729 was specifically required for activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314815

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Structural and evolutionary relationships among protein tyrosine phosphatase domains.

Authors:  J N Andersen; O H Mortensen; G H Peters; P G Drake; L F Iversen; O H Olsen; P G Jansen; H S Andersen; N K Tonks; N P Møller
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

2.  CD45 and RPTPalpha display different protein tyrosine phosphatase activities in T lymphocytes.

Authors:  D H Ng; M D Jabali; A Maiti; P Borodchak; K W Harder; T Brocker; B Malissen; F R Jirik; P Johnson
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

3.  CD45 tyrosine phosphatase activity and membrane anchoring are required for T-cell antigen receptor signaling.

Authors:  B B Niklinska; D Hou; C June; A M Weissman; J D Ashwell
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

4.  Specific interaction of the CD45 protein-tyrosine phosphatase with tyrosine-phosphorylated CD3 zeta chain.

Authors:  T Furukawa; M Itoh; N X Krueger; M Streuli; H Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Protein-tyrosine phosphatase activity of CD45 is activated by sequential phosphorylation by two kinases.

Authors:  D R Stover; K A Walsh
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

Review 6.  Protein tyrosine phosphatases: structure, function, and implication in human disease.

Authors:  Lutz Tautz; David A Critton; Stefan Grotegut
Journal:  Methods Mol Biol       Date:  2013

7.  Dissecting the catalytic mechanism of protein-tyrosine phosphatases.

Authors:  Z Y Zhang; Y Wang; J E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

8.  A synthetic lethal screen identifies a role for the cortical actin patch/endocytosis complex in the response to nutrient deprivation in Saccharomyces cerevisiae.

Authors:  Alison Care; Katherine A Vousden; Katie M Binley; Pippa Radcliffe; Janet Trevethick; Ilaria Mannazzu; Peter E Sudbery
Journal:  Genetics       Date:  2004-02       Impact factor: 4.562

9.  Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45.

Authors:  Hyun-Joo Nam; Florence Poy; Haruo Saito; Christin A Frederick
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

10.  The catalytic activity of the CD45 membrane-proximal phosphatase domain is required for TCR signaling and regulation.

Authors:  D M Desai; J Sap; O Silvennoinen; J Schlessinger; A Weiss
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.